Abstract: This invention provides a new class of medical devices and implants comprising amorphous metal alloys. The medical devices and implants may be temporary or permanent and may comprise other materials as well, such as polymers, ceramics, and conventional crystalline or polycrystalline metal alloys. Specifically, this invention provides an artificial heart component, such as an artificial heart valve or a pacemaker, wherein the artificial heart component includes an amorphous metal alloy component. The artificial heart valve may be a ball valve comprising an amorphous metal alloy cage. Alternatively, the artificial heart valve can include leaves made of amorphous metal alloy. The amorphous metal alloy component may also be a sheath or a strut. The pacemaker containing the amorphous metal alloy may house an energy source which is shielded from the body by the amorphous metal alloy.

Abstract: The present invention provides a valve configured for insertion on the proximal and distal sides of a heart valve annulus to replace the heart valve of a patient. The valve comprises a first substantially annular portion adapted to be positioned on a proximal side of the annulus of a patient and a second substantially annular portion adapted to be positioned on a distal side of the annulus of a patient, wherein at least one of the first and second substantially annular portions is movable towards the other portion to a clamped position to clamp around the annulus. The second portion has a flow restricting portion extending therefrom and is movable between a first position to permit the flow of blood and a second position to restrict the flow of blood. In one embodiment, the valve has a suture joining the first and second portions to draw the first and second portions into closer proximity and a cinch member to secure the suture to maintain the first and second portions in the clamped position.

Abstract: Described are methods and systems for modifying vascular valves in order to reduce retrograde blood flow through the valves. Preferred methods include connecting vascular valve leaflets with at least one remodelable material, such that the valve leaflets become fused by the ingrowth of the patient's native tissue. Preferred remodelable materials include collagenous extracellular matrix material, such as small intestine submucosa.

Abstract: The invention relates to heart valve xenografts from transgenic pigs having a disruption of an ?1-3 galactosyl transferase nucleic acid sequence and use of the xenografts for treating a patient.

Abstract: The invention is directed to apparatus and methods for seeding an implantable medical device, such as a vascular prosthesis, with cells, such as endothelial cells. The invention supports techniques for seeding a luminal surface of the device with axial centrifugation. Cells are introduced in suspension into the lumen of the device, and the device is subjected to centrifugation around a longitudinal axis defined by the lumen. Axial centrifugation causes the cells to concentrate toward the luminal surface. Shortly after axial centrifugation, the seeded device can be presented for implantation in a patient.

Abstract: A modified polyurethane including a lipid substituent pendant from at least one urethane nitrogen and/or at least one carbon atom of the modified polyurethane, methods of preparing modified polyurethanes and the use thereof as an implantable biomaterial.

Abstract: The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.

Abstract: Textured nanostructured surfaces are described which are highly resistant to cell adhesion. Such surfaces on medical implants inhibit fibroblast adhesion particularly on titanium treated silicone. The surfaces can also be engineered so that other cell types, such as endothelial and osteoblast cells, show little if any tendency to attach to the surface in vivo.

Abstract: An implantable prosthetic valve that is transformable from a first helical pre-implantation configuration to a second valvular functional configuration, and methods of delivery.

Abstract: Disclosed is a conduit that provides a bypass around an occlusion or stenosis in a coronary artery. The conduit is a tube adapted to be positioned in the heart wall to provide a passage for blood to flow between a heart chamber and a coronary artery, at a site distal to the occlusion or stenosis. The conduit has a section of blood vessel attached to its interior lumen which preferably includes at least one naturally occurring one-way valve positioned therein. The valve prevents the backflow of blood from the coronary artery into the heart chamber.

Abstract: The invention relates to a biological or artificial valve prosthesis (4, 5) for use in the human or animal body for replacement of an organ valve or a vessel valve, in particular a cardiac valve prosthesis or venous valve prosthesis, with a stent (8) or without a stent, with a supporting valve framework, with at least one valve (7) and with at least one conductor loop (2) that forms the inductance of an electrical resonance circuit. In order to provide a simple and inexpensive valve prosthesis that can be viewed in the MR imaging technique and is also easy to implant, the invention proposes that the at least one conductor loop (2) forms the valve framework and/or the valve (7) or supporting areas of the valve framework and/or supporting areas of the valve (7).

Abstract: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions. These polymeric regions, in turn, contain one or more polymers, at least one of which is a copolymer that includes a styrene monomer and an isobutylene monomer. Moreover, the styrene monomer content of the copolymer typically ranges from 25 to 50 mol %.

Abstract: This application is directed toward an improved method of synthesizing cationic siloxane prepolymers as well as a specific cationic siloxane prepolymer having improved compatibility with monofunctional siloxanyl methacrylate monomers and medical devices containing the cationic siloxane prepolymer.

Abstract: A method for making a bioprosthetic device to reduce post-implantation mineralization of the device is provided. The method comprises providing a collagen-containing material, removing cell debris from the collagen-containing material, crosslinking the material, and removing at least a portion of ester bonds from the crosslinked collagen-containing material. Ester bonds can be removed by exposing the collagen-containing material to hydrolyzing conditions or an enzyme.

Abstract: Developing heart valves are exposed to dynamic strains by applying a dynamic pressure difference over the leaflets. The flow is kept to a minimum, serving only as a perfusion system, supplying the developing tissue with fresh nutrients. Standard heart valves were engineered based on B trileaflet scaffolds seeded with cells isolated from the human saphenous vein. Tissue compaction is constrained by the stent, inducing increasing pre-strain in the tissue. The dynamic strains the tissues are exposed to via the dynamic pressure difference, are estimated using finite element methods based on the mechanical properties of the neo-tissue, in order to get inside into the strain distribution over the leaflet.

Abstract: An expandable type of heart valve prosthesis includes means for retaining the prosthesis substantially at a first cross-sectional dimension that is smaller than a second, expanded cross-sectional dimension, and for breaking down to permit the support structure to expand toward the second larger cross-sectional dimension after being implanted for a period of time.

Abstract: According to one aspect of the invention, a method of forming a medical device is provided, which includes: (a) contacting a substrate with a solution that contains (i) one or more types of polymers, (ii) a solvent that contains one or more types of solvent species, and (iii) one or more optional agents, for example, one or more therapeutic agents, among others; and (b) removing the solvent from the solution, thereby forming a polymeric layer on the substrate. The composition of the solution is changed over the course of forming the polymeric layer. In another aspect of the invention, a medical device is provided, which includes a substrate and a polymeric layer over the substrate. The polymeric layer contains a copolymer that contains differing first and second monomers. The lower surface of the polymeric layer contacting the substrate has a surface concentration of the first monomer relative to the second monomer that is higher than that of the upper surface of the polymeric layer opposite the substrate.

Abstract: An intraventricular apparatus includes an elongated body having a substantially tubular sidewall that extends substantially axially between spaced apart first and second ends, an opening located proximal the first end. A valve is located adjacent the first end to provide for substantially unidirectional flow of blood therethrough. At least one aperture extends through the tubular sidewall at an axial location between the valve and the second end to provide for substantially free flow of blood between an interior and an exterior of the sidewall.

Abstract: Methods for forming a support frame for flexible leaflet heart valves from a starting blank include converting a two-dimensional starting blank into the three-dimensional support frame. The material may be superelastic, such as NITINOL, and the method may include bending the 2-D blank into the 3-D form and shape setting it. A merely elastic material such as ELGILOY may be used and plastically deformed in stages, possibly accompanied by annealing, to obtain the 3-D shape. Alternatively, a tubular blank could be formed to define a non-tubular shape, typically conical. A method for calculating the precise 2-D blank shape is also disclosed. A mandrel assembly includes a mandrel and ring elements for pressing the blank against the external surface of the mandrel prior to shape setting.

Abstract: A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. The high elastin-containing biomaterial is further characterized by having anisotropic properties wherein the biological material has a greater stiffness in one direction and a greater elasticity in a cross direction. For instance, the biological material has an elastin content of about 30% by weight. In one embodiment, the biological material is vena cava tissue.

Abstract: Methods for forming a support frame for flexible leaflet heart valves from a starting blank include converting a two-dimensional starting blank into the three-dimensional support frame. The material may be superelastic, such as NITINOL, and the method may include bending the 2-D blank into the 3-D form and shape setting it. A merely elastic material such as ELGILOY may be used and plastically deformed in stages, possibly accompanied by annealing, to obtain the 3-D shape. Alternatively, a tubular blank could be formed to define a non-tubular shape, typically conical. A method for calculating the precise 2-D blank shape is also disclosed. A mandrel assembly includes a mandrel and ring elements for pressing the blank against the external surface of the mandrel prior to shape setting.

Abstract: A multiple-sided medical device comprises a closed frame of a single piece of wire or other resilient material and having a series of bends and interconnecting sides. The device has both a flat configuration and a second, folded configuration that comprises a self-expanding stent. The stent is pushed from a delivery catheter into the lumen of a duct or vessel. One or more barbs are attached to the frame of the device for anchoring or to connect additional frames. A covering of fabric or other flexible material such as DACRON, PTFE, or collagen, is sutured or attached to the frame to form an occlusion device, a stent graft, or an artificial valve such as for correcting incompetent veins in the lower legs and feet. A partial, triangular-shaped covering over the lumen of the device allows the valve to open with normal blood flow and close to retrograde flow.

Abstract: The present Specification describes materials and methods which provide for improved performance of medical prostheses, including vascular graft material, artificial heart valves, and other implanted materials. The materials comprising bound thrombomodulin or a functionally equivalent derivative protein, provide for fewer undesirable side effects including inflammation, thromboses and neointimal hyperplasia.

Abstract: An artificial heart valve comprising a tubular base body having sinuse(s) of Valsalva and valve cusp(s) provided inside the base body, characterized in that the base body and the valve cusps comprise a bioabsorbable polymer material.

Abstract: Vascular biomaterial structures may be coated with a plasma-induced layer on their surface. Vascular biomaterial structures may include cardiovascular devices such as heart valves, stents, vascular graphs, and the like. Devices coated with a plasma polymerized coating may show reduced amounts of undesirable coagulation of blood at the surface of the device. A reduced amount of thrombosis may be observed for such plasma coated medical devices.

Abstract: A bioprosthetic heart valve is disclosed. In a first aspect of the invention, a prosthetic heart valve comprises three mammalian heart valve leaflets, each valve leaflet including a full root length of tissue, the valve leaflets being affixed to one another to define a fluid flow passage, the fluid flow through which may be governed by the valve leaflets. In a second aspect the heart valve comprises a plurality of heart valve leaflets affixed to one another to define a fluid flow passage, the fluid flow through which may be governed by the valve leaflets; and a permanent trimming guide on at least one of the plurality of valve leaflets. In yet a third aspect of the invention, a bioprosthetic heart valve comprises a plurality of assembled parts, wherein the assembled parts are sutured together by hidden and locking stitches.

Abstract: A biomaterial useful for bioprostheses such as bioprosthetic heart valves is provided in which the fixed tissue has improved elastic properties. The high elastin-containing biomaterial is further characterized by having anisotropic properties wherein the biological material has a greater stiffness in one direction and a greater elasticity in a cross direction. For instance, the biological material has an elastin content of about 30% by weight. In one embodiment, the biological material is vena cava tissue.

Abstract: Implantable vascular devices and implantable cardiovascular devices suitable for contacting a patient's blood or bodily fluids include a polymer substrate that is at least partly coated with a diamond-like carbon coating. The diamond-like carbon coated polymer substrate can be flexible or rigid. Preferred medical devices include heart valve prostheses with leaflets or orifice rings formed from diamond-like carbon coated polymer materials. Preferred approaches for the deposition of the diamond-like carbon coating are performed at low pressures and include ion beam assisted deposition.

Abstract: The present invention relates to noval design of mechanical valve prostheses and manufacturing methods. A series of prosthetic valves with novel design and a unique manufacturing approach are disclosed. These devices possess unique designs and are made of nanostructurely engineered biomaterial. In addition, a novel manufacturing approach will be used to produce these devices because the convention technique is incapable of fabricating the devices due to the small size, design requirements and material properties restrain. Furthermore, it provides the convenience and thus low cost in manufacturing. The devices are particularly but not exclusively useful in human circulation system to restore the normal functions.

Abstract: The present invention provides a prosthetic heart valve that includes biologically active agents that retard or prevent the infiltration of fibrous tissue (“pannus”) from the host into the structure of the prosthetic valve. Preventing or decreasing the overgrowth of the prosthetic valve by pannus reduces the complications associated with the implantation and use of prosthetic heart valves.

Abstract: Methods for forming a support frame for flexible leaflet heart valves from a starting blank include converting a two-dimensional starting blank into the three-dimensional support frame. The material may be superelastic, such as NITINOL, and the method may include bending the 2-D blank into the 3-D form and shape setting it. A merely elastic material such as ELGILOY may be used and plastically deformed in stages, possibly accompanied by annealing, to obtain the 3-D shape. Alternatively, a tubular blank could be formed to define a non-tubular shape, typically conical. A method for calculating the precise 2-D blank shape is also disclosed. A mandrel assembly includes a mandrel and ring elements for pressing the blank against the external surface of the mandrel prior to shape setting.

Abstract: A prosthesis is formed from a biocompatible material having one or more associated cell adhesion stimulating proteins. The biocompatible material can be a ceramic material or a carbon coated material. The cell adhesion stimulating protein can be a structural protein or a polypeptide growth factor, such as vascular endothelial growth factor. Viable cells can be adhered in vivo or in vitro to the biocompatible material with the cell adhesion stimulating protein.

Abstract: Cardiovascular components such as biocompatible heart valves and annular sewing rings are disclosed, as well as, methods for making the same. The heart valves include biodegradable polymer fiber scaffolds and collagen. Also disclosed are donor aortic heart valves processed without the use of crosslinking chemicals.

Abstract: The invention relates to a cardiac valve prosthesis, comprising a support housing with at least two flaps, especially to a mitral cardiac valve. The flaps and/or the support housing have a core and a surface layer enclosing said core, the core material being characterized by a greater hardness and/or lesser flexural elasticity than the surface layer. For producing the cardiac valve according to the invention the inner surface layers of the flaps and the support body are produced as an integral part by at least one dip-coating step in a liquid solution. A support body core is then injection-molded onto said structure. In further dip-coating steps the flap core zones are formed and the outer surface layers of the flaps and the support body are finally produced in at least one further dip-coating step and the body so produced is then removed from the dip mold.

Abstract: An improved, non-resorbable annuloplasty ring that will provide support for the valve annulus while also promoting healing and/or regeneration of the annulus tissue is disclosed. Healing and/or regeneration of valvular tissue is promoted using a growth factor mixture that has been shown to be capable of promoting growth of a wide range of tissues, including heart valve tissue, and which promotes tissue growth based upon the local tissue environment (i.e., specific cell recruitment and proliferation). Thus, an annuloplasty ring that provides an actual healing response in addition to mechanical support to a dilated heart valve annulus is provided.

Abstract: The invention provides a molded valve leaflet containing a molded biopolymer having fibrils and cells within the molded biopolymer, wherein the fibrils of the molded biopolymer have commisure-to-commisure alignment. The invention also provides a valve equivalent containing a plurality of molded valve leaflets that are connected to a base, wherein the molded valve leaflets include a molded biopolymer having fibrils and cells within the molded biopolymer, wherein the fibrils of the molded biopolymer have commisure-to-commisure alignment.

Abstract: Vascular biomaterial structures may be coated with a plasma-induced layer on their surface. Vascular biomaterial structures may include cardiovascular devices such as heart valves, stents, vascular graphs, and the like. Devices coated with a plasma polymerized coating may show reduced amounts of undesirable coagulation of blood at the surface of the device. A reduced amount of thrombosis may be observed for such plasma coated medical devices.

Abstract: Biocompatible prostheses, specifically, biocompatible heart valves, are described which comprise a blend of a polyurethane (PU) and a polysiliconeurethane (PSU). Preferably, the polyurethane is a polyetherurethane (PEU). More preferably, it is a polyetherurethane urea (PEUU). Such prostheses typically exhibit reduced mineralization or thrombosis and/or reduced biological degradation.

Abstract: The present invention provides a heart valve prosthesis device having an occluder, an occluder base and a suture ring, where the occluder base and suture ring have a coating of anti-thrombotic/anti-fibrotic/anti-pannus material on the surface of the occluder base to approximately one-half to two-thirds to the outer peripheral edge of the suture ring, wherein the coating prevents thrombus, fibrosis and pannus from forming on the surfaces it coats. For example, the invention provides an improved heart valve prosthesis device, where the heart valve prosthesis is a mechancical heart valve, or a bioprosthetic heart valve.

Abstract: A suturing ring to attach the body of an implantable heart valve to heart tissue by sutures is composed of a fabric containing an inorganic antimicrobial agent. The fabric can have a material coating the fibers of the fabric in which particles of the agent are embedded. The coating material can be elastomeric and the fabric porous, to improve its flexibility, or non-porous and the fabric ring can be coated with a tissue compatible substance such as collagen. One type of ring has an annular top part to fit over one of top and bottom surfaces of the valve body and defining an opening to the heart valve, a step wall depending from the annular top part to extend along said valve body wall and an outwardly extending flange through which the sutures are to be sewn.

Abstract: A mechanical prosthetic heart valve with a pyrolytic carbon valve body having re-enforcing fibers in the valve body. The fibers may be short segments of graphite wire or continuous fibers may be wrapped around the valve body. The fiber may be arranged in loops and formed in repeating patterns around the valve body. Also, methods for making a prosthetic heart valve body having a first layer of pyrolytic carbon that is substantially free from fiber, a second layer comprised of fibers encased in pyrolytic carbon, and a third layer that is substantially free from fiber. The method may comprise placing a mandrel in a fluidized bed, coating the mandrel with a first layer of pyrolytic carbon, introducing a fiber, coating the mandrel and the fiber with a second layer of pyrolytic carbon, and coating the mandrel with a third layer of pyrolytic carbon.

Abstract: A prosthesis having an apertured structure is located in a chamber (11) which is taken to sub-atmospheric pressure. Once sub-atmospheric pressure has been reached, a liquid, optionally containing pharmacological agents, is introduced into the chamber. Drawn by the sub-atmospheric pressure, the liquid saturates the apertured structure of the prosthesis. In this way, the invention eliminates the risk of air being trapped in the apertured structure that could give rise to the formation of blood clots after implantation of the prosthesis. The liquid can contain drugs that penetrate the prosthesis, performing their therapeutic action locally and over time after implantation.

Abstract: The present invention relates to a heart valve prosthesis having an annular body with a pair of flanges, and a closing element in the form of two or three flaps mounted through bearings into the body's recesses with freedom to be rotated. The annular body has a constant height on a greater portion of a ring circle, and a number of ledges equal to that of the flaps. The ledges are provided with flap rotation limiters. The flaps have ascending and descending surfaces oriented to the direct and reverse flow of blood, a side edge and an edge for joining the other flap. The descending surface of a flap is flat and the ascending surface thereof is spherically concave. The flaps have the minimal thickness on an axis of symmetry at the joining edge. The axes of rotation of the three flap embodiment are arranged relative to each other at an angle of 60° thereby to form the sides of an equilateral triangle. For the valve with two flaps the flange facing the direct flow of blood is thickened.

Abstract: An implantable prosthesis can be formed from an improved biocompatible material that provides for cellular colonization of the biocompatible material. Specifically, the biocompatible material is a rigid porous material. In embodiments of particular interest, the implantable prosthesis is a mechanical heart valve prosthesis with a rigid occluder. In some embodiments, the rigid occluder is formed from the biocompatible material. A filler comprising a hydrogel or a structural protein can be located within the pores. In some embodiments, a bioactive agent is within the pores. In some embodiments, the rigid occluder is formed from a polymer material, a carbonaceous solid or a ceramic material. The pores can extend through the rigid material.

Abstract: A heart valve prosthesis for use as an aortic or pulmonary replacement valve, or as a mitral or tricuspid valve includes leaflets that are reinforced through the use of oriented fiber components in a laminated composite, in which the leaflets of the valve are reinforced with fiber-reinforcing materials oriented along lines of stress in the material, thus to provide a long-lived valve that provides strength at points of maximal stress that have hitherto been foci for material failure. In a preferred embodiment involving a stentless valve, the reinforcing materials are optimized in terms of the density and orientation of the fibers in the composite materials, thus to extend the life of a stentless valve, with the valve requiring no anti-coagulants as is the case with mechanical valves and exhibiting no hemolysis in which red cells are damaged by the action of mechanical valves. Longevity exceeds thirty five years in most cases, making replacement of such a valve a remote possibility.

Abstract: This invention relates to improvements in prosthetic cardiac and venous valves and implantable medical devices having moveable septa. The inventive prosthetic cardiac and venous valves have metallic or pseudometallic valves coupled to metallic or pseudometallic stents that permit percutaneous delivery of the devices.

Abstract: Crosslinked tissue is contacted with one or more toxicity reducing solutions to remove cytotoxicity associated with the crosslinking process. In particular, crosslinked tissue can be contacted with an inorganic sulfur-oxygen group to form chemical adducts of aldehydes and the inorganic sulfur-oxygen group. Preferably, the cytotoxicity reduced crosslinked tissue has no residual cytotoxicity. In preferred embodiments, a plurality of toxicity reducing agents are used to detoxify the tissue. Preferred toxicity reducing agents include, for example, inorganic sulfur-oxygen ions, such as bisulfate and thiosulfate, organic sulfates, amines, ammonia/ammonium, and surfactants.

Abstract: A non-elastomeric polyurethane composition which includes a first chain extender of the general formula (I) wherein R1, R2, R3, R4, R5, and R6 are the same or different and selected from an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical; R7 is a divalent linking group or an optionally substituted straight chain, branched or cyclic, saturated or unsaturated hydrocarbon radical; and n is 0 or greater, and a second chain extender.

Abstract: Cardiovascular components such as biocompatible heart valves and annular sewing rings are disclosed, as well as, methods for making the same. The heart valves include biodegradable polymer fiber scaffolds and collagen. Also disclosed are donor aortic heart valves processed without the use of crosslinking chemicals.

Abstract: Biocompatible prostheses, specifically, biocompatible heart valves, are described which comprise a blend of a polyurethane (PU) and a polysiliconeurethane (PSU). Preferably, the polyurethane is a polyetherurethane (PEU). More preferably, it is a polyetherurethane urea (PEUU). Such prostheses typically exhibit reduced mineralization or thrombosis and/or reduced biological degradation.